About Integra Lifesciences Holdings Corp
- Industry: Health Care
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.integralife.com/
Frequently Asked Questions
What is the 52-week range for IART?
The 52-week high is $20.49 and the 52-week low is $8.7.
What is the P/E ratio for IART?
The P/E ratio data is currently unavailable.
What is the dividend yield for IART?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -0.70%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -0.44%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.93.
Analyst Recommendation Trends
Wall Street analyst consensus for IART over the last few months:
Latest IART News
Why Integra LifeSciences (IART) Stock Is Nosediving
Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 15.3% in the morning session after the company released preliminary third-quarter 2026 results and reduced its full-year revenue and adjusted EPS guidance due to operational disruption caused by a July 2026 flood at its Cincinnati facility.
Sector Update: Healthcare Stocks Steady Late Afternoon
Healthcare stocks were little changed late Friday afternoon with the NYSE Healthcare Index and the S
These stocks are moving in today's session
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Crude Oil Down Over 1%; US Factory Orders Edge Higher In August
U.S. stocks rose Friday, led by Nasdaq (+1.27%), despite weak jobs data. Factory orders edged up; oil and gold fell. Alpha Modus surged 213%.
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Stablecoin Development (AMEX:SDEV) shares moved upwards by 66.9% to $6.11 during Friday's regular session. The company's market cap stands at $99.2 million. QTREX Quantum (NASDAQ:QTEX) stock rose
Friday's pre-market session: top gainers and losers
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance. “Our third quarter results were impacted by the July flooding event at our Cincinnati facility,” said Stuart Essig, Chairman and Chief Executive Officer. “Our teams have made significant progress executing recovery plans and supporti
Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B
PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of a proposed $600 million seven-year Senior Secured Term Loan B as part of a broader refinancing transaction. The Company intends to use the net proceeds from the Term Loan B, together with other sources of financing, to refinance certain of its existing indebtedness and pay associated fees and expenses. “This transa
Integra LifeSciences Anticipates Flooding Related Supply Disruption To Impact Q3 Revenue By ~$7M, Q4 Revenue By $15M - $20M; Expects Q3 Revenue Range Of ~$410M - $412M, Adjusted EPS Range $0.55 - $0.59; Updates FY26 Adjusted EPS Range From $2.40 - $2.50 To $2.30 - $2.40, Revenue Range From $1.654B - $1.695B To $1.634B - $1.654B
Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026
IART vs. PEN: Which Stock Is the Better Value Option?
IART vs. PEN: Which Stock Is the Better Value Option?
Should You Continue to Hold IART Stock in Your Portfolio?
Integra sees steady Specialty Surgery demand and improving efficiency, but leverage and currency swings remain key challenges for Integra.
IART or PEN: Which Is the Better Value Stock Right Now?
IART vs. PEN: Which Stock Is the Better Value Option?
Integra LifeSciences Announces 100th Patient Enrolled in AERA® Pediatric Registry
Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients ACCLARENT AERA® Eustachian Tube Balloon Dilation System ACCLARENT AERA® Eustachian Tube Balloon Dilation System PRINCETON, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences (Nasdaq: IART), a leading global medical technology company, announced today the enrollment of the 100th patient in the AERA® Pediatric Registry, a prospective, multicenter observational registry evaluating the real-worl
Integra LifeSciences Enrolls 100th Participant In Its AERA Pediatric Registry Observational Registry
Integra LifeSciences (Nasdaq: IART), a leading global medical technology company, announced today the enrollment of the 100th patient in the AERA® Pediatric Registry, a prospective, multicenter observational registry
1 of Wall Street’s Favorite Stocks with Impressive Fundamentals and 2 We Turn Down
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Integra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026
Company to feature surgeon-led educational programming and technologies supporting liver surgery CUSA MicroFrance CUSA Clarity Laparoscopic Tip and MicroFrance Laparoscopic Bipolar Forceps - precision, handmade instruments created with the notion that Millimeters of Accuracy matter. PRINCETON, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences (Nasdaq: IART) will mark 20 years of CUSA® technology within its portfolio at the American College of Surgeons (ACS) Clinical Congress 2026, ta
Integra LifeSciences (IART) Stock May Be 48% Undervalued On Cash Flow
Integra LifeSciences Holdings has a share price of US$16.02 after a mixed stretch that includes both a sharp multi-year decline and a solid gain this year. With the market clearly reassessing the story, the open question is whether the current Integra LifeSciences valuation is supported by the cash the business can generate over time. Over the past 5 years, the stock has fallen 77.3%, which puts the focus squarely on whether the cash flowing out of the business can justify where the shares...
Integra LifeSciences Holdings Corporation (IART) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Integra LifeSciences Holdings Corporation (IART) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 4:05 PM EDTCompany...
Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks
Let’s dig into the relative performance of Integra LifeSciences (NASDAQ:IART) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - specialty earnings season.
3 Reasons IART is Risky and 1 Stock to Buy Instead
What a time it’s been for Integra LifeSciences. In the past six months alone, the company’s stock price has increased by a massive 70.2%, reaching $16.26 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, and Michael McBreen, chief commercial officer, will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 2:15 p.m. ET. Stuart Essig, chairman and chief executive officer, will present at the 2026 Morgan Stanley Healthcare Conference on Tuesday, Septe
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-01 | Veillon-Berteloot Chantal | -1,455 | $16.62 | $24,182 |
| 2026-07-03 | Knight Lea Daniels | -5,226 | $18.05 | $94,329 |
| 2026-07-01 | Singh Harvinder | +5,590 | - | - |
| 2026-07-01 | Mosebrook Jeffrey | -937 | $17.89 | $16,763 |
| 2026-07-01 | DAVIS ROBERT T. JR. | +11,180 | - | - |
| 2026-06-01 | McBreen Michael J. | +31,909 | - | - |
| 2026-06-01 | McBreen Michael J. | +60,372 | - | - |
| 2026-06-01 | ESSIG STUART | +365,297 | - | - |
| 2026-06-01 | ESSIG STUART | +705,468 | - | - |
| 2026-05-09 | BRADLEY KEITH | -882 | $13.92 | $12,277 |
| 2026-05-07 | Lo Renee Wonlai | +17,700 | - | - |
| 2026-05-07 | Clay Shaundra | +17,700 | - | - |
| 2026-05-07 | GRAVES JEFFREY A | +17,700 | - | - |
| 2026-05-07 | HILL BARBARA B | +17,700 | - | - |
| 2026-05-07 | HILL BARBARA B | +6,638 | - | - |
| 2026-05-07 | SCHADE CHRISTIAN S | +17,700 | - | - |
| 2026-05-07 | BRADLEY KEITH | +17,700 | - | - |
| 2026-03-11 | Veillon-Berteloot Chantal | +41,783 | - | - |
| 2026-03-11 | Veillon-Berteloot Chantal | -5,420 | $9.61 | $52,086 |
| 2026-03-11 | Knight Lea Daniels | +111,179 | - | - |
| 2026-03-11 | Knight Lea Daniels | -8,089 | $9.61 | $77,735 |
| 2026-03-11 | Singh Harvinder | +60,865 | - | - |
| 2026-03-11 | Singh Harvinder | -16,566 | - | - |
| 2026-03-11 | Singh Harvinder | -2,356 | - | - |
| 2026-03-11 | Singh Harvinder | -5,190 | $9.61 | $49,876 |
| 2026-03-11 | Singh Harvinder | +18,922 | - | - |
| 2026-03-11 | Singh Harvinder | -861 | $9.61 | $8,274 |
| 2026-03-11 | McBreen Michael J. | +92,108 | - | - |
| 2026-03-11 | McBreen Michael J. | -7,247 | $9.61 | $69,644 |
| 2026-03-11 | Poul Mojdeh | +343,393 | - | - |
| 2026-03-11 | Mosebrook Jeffrey | +15,957 | - | - |
| 2026-03-11 | Mosebrook Jeffrey | -806 | $9.61 | $7,746 |
| 2026-03-11 | Hutchinson Michael Damon | +70,305 | - | - |
| 2026-03-11 | DAVIS ROBERT T. JR. | +43,350 | - | - |
| 2026-03-11 | DAVIS ROBERT T. JR. | -8,487 | $9.61 | $81,560 |
| 2026-03-10 | Singh Harvinder | -1,216 | - | - |
| 2026-03-10 | Singh Harvinder | -601 | $9.55 | $5,740 |
| 2026-03-10 | Singh Harvinder | +1,216 | - | - |
| 2026-03-10 | McBreen Michael J. | -2,354 | $9.55 | $22,481 |
| 2026-03-10 | Mosebrook Jeffrey | -341 | $9.55 | $3,257 |
| 2026-03-10 | DAVIS ROBERT T. JR. | -687 | $9.55 | $6,561 |
| 2026-02-02 | Hutchinson Michael Damon | +89,606 | - | - |
| 2026-01-06 | Poul Mojdeh | -542 | - | - |
| 2026-01-06 | Poul Mojdeh | -848 | - | - |
| 2026-01-06 | Poul Mojdeh | -542 | $13.13 | $7,116 |
| 2026-01-06 | Poul Mojdeh | -848 | $13.13 | $11,134 |
| 2026-01-06 | Poul Mojdeh | +542 | - | - |
| 2026-01-06 | Poul Mojdeh | +848 | - | - |
| 2025-11-05 | GRAVES JEFFREY A | +9,000 | $11.35 | $102,150 |
| 2025-10-12 | Singh Harvinder | -11,965 | - | - |
| 2025-10-12 | Singh Harvinder | -3,281 | $13.34 | $43,769 |
| 2025-10-12 | Singh Harvinder | +11,965 | - | - |